市场立即捐赠成为会员

购物车 (0)

DIA会员及用户请点击登录

登录

忘记用户 ID？ or 忘记密码？

Not a Member?

创建账户并加入。

Tokyo Big Sight

2017 年 11 月 12 日 9:30 上午 - 2017 年 11 月 14 日 5:30 下午

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

14th DIA Japan Annual Meeting 2017

返回 Agenda

[V7-S3] Current Status on Counterfeit Medicines in Global and Issues on Japanese Market

Session Chair(s)

Yoshiaki Ohashi, PHD

Yoshiaki Ohashi, PHD

Audit and Supervisory Board Member, Chugai Pharmaceutical Co.,Ltd., Japan

The threat of counterfeit medicines is increasing worldwide, and it creates serious risks to patient safety. In particular, many cases of medicines purchased over the internet have been found to be counterfeit. Therefore, it is necessary that pharmaceutical companies take initiatives including implementation of anti-counterfeiting technologies and working with Customs and law enforcement agencies. In Japanese medicine market, it has been traditionally considered that counterfeit medicines would not be distributed, however, the “Harvoni” case indicates it would no longer true and can be a tip of the iceberg. In this session, trend of counterfeit medicines in global market, as well as the corrective actions, would be first introduced. And then, panelists from NPO, industry and academia will discuss potential risks and necessary actions in Japanese market, in order to secure patient safety as well as medicine quality.

Speaker(s)

Martin Blair

Martin Blair

Asia Pacific Regional Manager, Pharmaceutical Security Institute (PSI), Thailand

Global Situation Report 2016

Kazuko Kimura, PHD

Prof. of Special-Appointment, MQS, Kanazawa University, Japan

Falsified Medicines in Japan

Pius Waldmeier, PHD

Pius Waldmeier, PHD

Head of Supply Chain Projects Mgt; Head of GRACC, Pharma Global Technical Ops, F. Hoffmann-La Roche, Ltd., Switzerland

ANTI-COUNTERFEIT ACTIVITIES AT HOFFMANN –LA ROCHE

Scott Kammer, MA

Scott Kammer, MA

Director, Global Product Protection, Takeda Pharmaceuticals U.S.A., Inc., United States

A Company Framework, Objectives and Risk